Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Renalof is a dietary supplement and herbal product developed by Catalysis S.L., primarily indicated for the dissolution and elimination of renal and biliary calculi (kidney and gallstones). It is derived from the rhizome extract of *Agropyron repens* (couch grass), which is processed using a molecular activation technology to enhance its therapeutic efficacy. The product exhibits diuretic and demineralizing properties, specifically targeting the disintegration and painless elimination of calcium oxalate and struvite stones from the genitourinary system. Clinical evaluations, including Phase 3 trials, have investigated its role in reducing stone volume, improving physicochemical parameters, and preventing recurrence in patients with urolithiasis and cholelithiasis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Renalof.